Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 1.00 |
| ▸ | CAPN1 | P07384 | 14/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078877 | 0.97 | CTSK (0.95) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| Lithium Ion SCHEMBL913545 | 0.97 | CTSK (0.95) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL2079725 | 0.97 | CTSK (0.95) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| Potassium Ion SCHEMBL913496 | 0.97 | CTSK (0.95) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL6735420 | 0.86 | CTSK (0.76) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL7206790 | 0.86 | CTSK (0.76) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL913603 | 0.86 | CTSK (0.76) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL913547 | 0.85 | CTSK (0.74) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL2730672 | 0.85 | CTSK (0.74) | CTSKCAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL14345721 | 0.82 | CTSK (0.69) | CTSKCAPN1CTSBCAPN9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-8163942-B2 | Salt of (2S, 3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid | VELCURA THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-1619190-B1 | SALTS OF (2S,3S)-3- [[(1S)-1-ISOBUTOXYMETHYL-3-METHYLBUTYL]CARBAMOYL] OXIRANE-2-CARBOXYLIC ACID | NIPPON CHEMIPHAR CO (JP) | 2010-12-29 | — | — | EP | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-8163942-B2 | Salt of (2S, 3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid | VELCURA THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| JP-2011241148-A | SOLID PREPARATION FOR MEDICAL USE | NIPPON CHEMIPHAR CO LTD | 2011-12-01 | — | — | JP | disclosed |
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2011037100-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR GUM DISEASE OR APICAL PERIODONTITIS | 日本ケミファ株式会社 (JP) | 2011-03-31 | — | — | WO | disclosed |
| US-20110003993-A1 | SALT OF (2S, 3S) -3- [ [ (1S) -1- ISOBUTOXYMETHYL-3-METHYLBUTYL] CARBAMYL] OXIRANE-2-CARBOXYLIC ACID | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| WO-2010027101-A1 | SOLID PREPARATION FOR MEDICAL USE | 日本ケミファ株式会社 (JP) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | IRAK4, IRAK1, IRAK2 | CTSK 3885/4885CAPN1 3161/4885CTSB 3770/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CTSK 4222/4885CAPN1 4648/4885CTSB 4429/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSK 11/4885CAPN1 226/4885CTSB 2/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CTSK 2995/4885CAPN1 2602/4885CTSB 2257/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CTSK 1332/4885CAPN1 586/4885CTSB 700/4885 |
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | SERPINB1, ECE1, MME | CTSK 141/4885CAPN1 219/4885CTSB 100/4885 |
| US-20110003993-A1 | SALT OF (2S, 3S) -3- [ [ (1S) -1- ISOBUTOXYMETHYL-3-METHYLBUTYL] CARBAMYL] OXIRANE-2-CARBOXYLIC ACID | SLC7A1, CACNA1S, SLC7A5 | CTSK 823/4885CAPN1 663/4885CTSB 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.